Serum Tumour Markers in Testicular and Extragonadal Germ Cell Malignancies

References

• Krag Jacobsen G, Barlebo H, Olsen J, Scultz H P, Starklint H, Søgaard H. Væth M and the DATECA Study Group: Testicular germ cell tumours in Denmark 1976–1980; Pathology of 1058 consecutive cases. Acta Radiologica Oncology 1984; 23: 239–247
   PubMedGoogle Scholar
• Klepp O. Nonseminomatous germ cell testis cancer: Therapeutic outcome and prognostic factors. Dissertation thesis, University of Trondheim Faculty of Medicine, Trondheim 1991
   Google Scholar
• Peckham M. Testicular cancer. Acta Oncologica 1988; 27: 439–453
   PubMed Web of Science ®Google Scholar
• Beastall G H, Cook B, Rustin G JS, Jennings J. A review of the role of established tumour markers. Ann Clin Biochem 1991; 28: 5–18
   PubMedGoogle Scholar
• Bates S E, Longo DL. Use of serum tumor markers in cancer diagnosis and management. Seminars in Oncology 1987; 14: 102–138
   PubMed Web of Science ®Google Scholar
• Waldman T A, McLntire KR. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer 1974; 34: 1510–1515
   Google Scholar
• Trichopoulos D, Sizaret P, Tabor E, et al. Aplhafetoprotein levels of liver cancer patients and controls in a European population. Cancer 1980; 46: 736–740
   PubMed Web of Science ®Google Scholar
• Klepp O, Flodgren P, Maartman-Moe H, Lindholm C E, Unsgaard B, Teigum H, FossS SD, Paus E. Early Clinical Stages (CS1, CSlMk+ and CS2A) of Non-seminomatous Testis Cancer. Value of Pre-and Post-Orchiectomy Serum Tumor Marker Information in Prediction of Retroperitoneal Lymph Node Metastases. Annals of Oncology 1990; 1: 281–288
   PubMed Web of Science ®Google Scholar
• Nørgaard-Pedersen B, Schultz H P, Arends J, Brincker H, Krag Jacobsen G, Linde Løv B, Rørth M, ven Nekjaer SIL. Tumour markers in testicular germ cell tumours -Five-year experience from ihe DATECA Study 1976–1980. Acta Radiologica Oncology 1984; 23: 287–294
   PubMed Web of Science ®Google Scholar
• Vaitukaikis J L, Ross G T, Braunstein GD, et al. Gonadotropins and their subunit: Basic and clinical studies. Recent Prog Horm Res 1976; 32: 289–331
   PubMedGoogle Scholar
• Fossa A, Fossa SD. Serum lactate dehydrogenase and human choriogonadotrophin in seminoma. Br J Urol 1984; 63: 408–15
   Google Scholar
• Lieskowsky G, Skinner DG. Significance of serum lactate dehydrogenase in stages B and C non-seminomatous testis tumors. J Urol 1980; 123: 516–17
   PubMedGoogle Scholar
• Carney D NJ, Jide D C, Cohen MH, et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy for small-cell lung cancer. Lancet 1982; i: 583–585
   Google Scholar
• Zeltzer P M, Marangos P J, Evans A E, Schneider SL. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 1986; 57: 1230–1234
   PubMed Web of Science ®Google Scholar
• Wibe E, Paus E, Aamdahl S. Neuron specific enolase (NSE) in serum of patients with malignant melanoma. Cancer Letters 1990; 52: 29–31
   PubMed Web of Science ®Google Scholar
• Kuzmits R, Schernthaner G, Krisch K. Serum neuron-specific enolase. A marker for response to therapy in seminoma. Cancer 1987; 60: 1017–1021
   PubMed Web of Science ®Google Scholar
• Takashi M, Haimoto H, Nagai T, Koshikawa T, Kato K. Enolase isoenzymes in seminoma. Urol Res 1990; 18: 175–80
   PubMedGoogle Scholar
• Fossa S D, Klepp O, Paus E. Neuron-specific enolase. A serum tumour marker in seminoma?. Submitted to Br J Cancer
   Google Scholar
• Nielsen O S, Munro A J, Duncan W, Sturgeon J, Gospodarowicz M K, Jewett M AS, Malkin A, Thomas GM. Is placental alkaline phosphatase (PLAP) a useful marker for seminoma?. Eur J Cancer 1990; 26: 1049–1054
   PubMed Web of Science ®Google Scholar
• Gedde-Dahl T, Hannisdal E, Klepp OG, Røttum K A, Waksvik H, Fossa S D, Stenwig A E, Brøgger A. Testicular neoplasm occuring in four brothers. A search for a genetic disposition. Cancer 1985; 55: 2005–2009
   PubMed Web of Science ®Google Scholar
• Horwich A, Brada M, Nicholls J, Jay G, Hendry W F, Dearnalay D, Peckham MJ. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 1989; 25: 177–184
   PubMedGoogle Scholar
• Fosså SD, Aass N, Kaalhus O. Testicular cancer in young Norwegians. J Surg Oncol 1988; 39: 43–63
   PubMedGoogle Scholar
• Lippert M C, Javadpour N. Lactic dehydrogenase in the monitoring and prognosis of testicular cancer. Cancer 1981; 48: 2274–2278
   PubMed Web of Science ®Google Scholar
• von Eyben F E, Skude G, Fosså SD, Klepp O, Børmer O. Serum lactate dehydrogenase (S-LDH) and S-LDH Isoenzymes in patients with testicular germ cell tumors. Mol Gen Genet 1983; 189: 326–333
   PubMedGoogle Scholar
• Aass N, Klepp O, Cavallin-Ståhl E, Dahl O, Wicklund H, Unsgaard B, Baldetorp L, AhlstRøm S, Fosså SD. Prognostic Factors in Unselected Patients with Advanced Non-Seminomatous Metastatic Testicular Cancer A Multicentre Experience. J Clin Oncol May issue?, 1991, In press
   PubMedGoogle Scholar
• von Eyben F E, Blaabjerg O, Hyltoft Petersen P, Hørder M, Nielsen H V, Kruse Andersen S, Parlev E. Lactate dehydrogenase isoenzyme 1 in testis cancer. Lancet 1987; ii: 1035–36
   Google Scholar
• Paus E, Fosså A, Fosså SD, Nustad K. High frequency of incomplete human chorionic gonadotropin in patients with testicular seminoma. J Urol 1988; 139: 542–44
   PubMedGoogle Scholar
• Klepp O, Olsson A M, Henrikson H, Aass N, Dahl O, Stenwig A E, Persson B E, Cavallin-Stahl E, Fossa S D, Wahlqvist L. Prognostic Factors in Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Multivariate Analysis of a Prospective Multicenter Study. J Clin Oncol 1990; 8: 509–518
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party on Testicular Tumours: Prognostic factors in advanced non-seminomatous germ cell testicular tumours: results of a multicentre study. Lancet 1985; I: 8–11
   Google Scholar
• Stoter G, Sylvester R, Sleijfer D T, ten-Bokkel Huinink W W, Kaye S B, Jones W G, Van Oosterom A T, Vendrik C P, Spander P, de Pauw M. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from a European organization for research on treatment of cancer multiinstitutional phase III study. Cancer Res 1987; 47: 2714–2718
   PubMedGoogle Scholar
• Bajorin D, Katz A, Chan E, Geller N, Vogelsang N, Bosl GJ. Comparison of criteria for assigning germ cell tumor patients to “good risk” and “poor risk” studies. J Clin Oncol 1988; 6: 786–792
   PubMed Web of Science ®Google Scholar
• Price P, Hogan SJ, Horwich A. The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time -1. Theoretical basis and practical implication. Eur J Cancer 1990; 26: 450–453
   PubMed Web of Science ®Google Scholar
• Price P, Hogan SJ, Bliss J M, Horwich A. The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time - II. Prognostic significance in patients treated with chemotherapy. Eur J Cancer 1990; 26: 453–457
   PubMedGoogle Scholar
• Duchesne G M, Horwich A, Dearnley D P, Nicholls J, Peckham M J, Hendry WF. Orchidectomy alone for stage I seminoma of the testis. Cancer 1990; 65: 1115–1118
   PubMed Web of Science ®Google Scholar
• Toner G C, Geller N L, Lin S Y, Bosl GJ. Exttagonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. Cancer 1991; 67: 2049–2057
   PubMed Web of Science ®Google Scholar
• Toner G C, Geller N L, Tan C, Nisselbaum J, Bosl GJ. Serum marker half-life during chemomerapy allows early prediction of complete respons and survival in nonseminomatous germ cell tumors. Cancer Research 1990; 50: 5904–5910
   PubMed Web of Science ®Google Scholar
• Peckham M. Testicular cancer. Reviews in Oncology 1988; 1: 439–453, in Acta Oncologica 1988 27. Fasc.4
   Google Scholar
• Pizzocaro G, Zanoni F, Salvioni R, Milani A, Piva L, Pilotti S. Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 1987; 138: 1393–1396
   PubMed Web of Science ®Google Scholar
• Swenotecaii Treatment of clinical stage I (CS1) non-seminomatous testicular cancer. Study Protocol 1991 Tumorregistret. Lasarettet i Lund, LundSweden. 85: S-221
   Google Scholar
• Hamilton C R, Horwich A, Easton D, Peckham M. Radiotherapy for stage I seminoma testis. result of treatment and complications. Radiother Oncol 1986; 6: 115
   PubMed Web of Science ®Google Scholar